Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues.

Abstract

BACKGROUND:

Guidelines for prevention of group B streptococcal (GBS) infection have successfully reduced early onset (EO) GBS disease. Study results suggest that Escherichia coli is an important EO pathogen.

OBJECTIVE:

To determine EO infection rates, pathogens, morbidity, and mortality in a national network of neonatal centers.

METHODS:

Infants with EO infection were identified by prospective surveillance at Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Network centers. Infection was defined by positive culture results for blood and cerebrospinal fluid obtained from infants aged ≤72 hours plus treatment with antibiotic therapy for ≥5 days. Mother and infant characteristics, treatments, and outcomes were studied. Numbers of cases and total live births (LBs) were used to calculate incidence.

RESULTS:

Among 396 586 LBs (2006-2009), 389 infants developed EO infection (0.98 cases per 1000 LBs). Infection rates increased with decreasing birth weight. GBS (43%, 0.41 per 1000 LBs) and E coli (29%, 0.28 per 1000 LBs) were most frequently isolated. Most infants with GBS were term (73%); 81% with E coli were preterm. Mothers of 67% of infected term and 58% of infected preterm infants were screened for GBS, and results were positive for 25% of those mothers. Only 76% of mothers with GBS colonization received intrapartum chemoprophylaxis. Although 77% of infected infants required intensive care, 20% of term infants were treated in the normal newborn nursery. Sixteen percent of infected infants died, most commonly with E coli infection (33%).

CONCLUSION:

In the era of intrapartum chemoprophylaxis to reduce GBS, rates of EO infection have declined but reflect a continued burden of disease. GBS remains the most frequent pathogen in term infants, and E coli the most significant pathogen in preterm infants. Missed opportunities for GBS prevention continue. Prevention of E coli sepsis, especially among preterm infants, remains a challenge.

• Authors: Barbara J Stoll, Nellie I Hansen, Pablo J Sánchez, Roger G Faix, Brenda B Poindexter, Krisa P Van Meurs, Matthew J Bizzarro, Ronald N Goldberg, Ivan D Frantz 3rd, Ellen C Hale, Seetha Shankaran, Kathleen Kennedy, Waldemar A Carlo, Kristi L Watterberg, Edward F Bell, Michele C Walsh, Kurt Schibler, Abbot R Laptook, Andi L Shane, Stephanie J Schrag, Abhik Das, Rosemary D Higgins, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
• Journal: Pediatrics (Pediatrics) Vol. 127 Issue 5 Pg. 817-26 (May 2011) ISSN: 1098-4275 [Electronic] United States
• PMID: 21518717 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Anti-Bacterial Agents

Topics

• Age of Onset
• Anti-Bacterial Agents (therapeutic use)
• Bacteremia (drug therapy, epidemiology, prevention & control)
• Escherichia coli (isolation & purification)
• Escherichia coli Infections (drug therapy, epidemiology, prevention & control)
• Female
• Follow-Up Studies
• Humans
• Incidence
• Infant, Newborn
• Infant, Premature
• Male
• Neonatal Screening (organization & administration)
• Primary Prevention (organization & administration)
• Registries
• Retrospective Studies
• Risk Assessment
• Streptococcal Infections (drug therapy, epidemiology, prevention & control)
• Streptococcus agalactiae (isolation & purification)
• Survival Analysis
• United States